Research Overview of Aranesp
Aranesp 20 mcg is a recombinant human erythropoietin analogue manufactured by Amgen for advanced laboratory research applications. This pharmaceutical-grade compound represents a longer-acting form of erythropoietin with enhanced N-linked glycosylation, specifically designed for investigating hematopoietic regulation mechanisms in controlled research environments. Scientists studying erythropoiesis pathways can examine how this glycoprotein hormone analogue influences red blood cell production through its interaction with erythropoietin receptors. The compound’s extended serum half-life compared to native erythropoietin makes it particularly valuable for research protocols requiring sustained bioactivity. Researchers at Stroid UK Shop utilise Aranesp to investigate renal disease mechanisms, cancer-related anemia pathways, and bone marrow response characteristics in various experimental models.
Laboratory Research Applications
In laboratory settings, researchers study Aranesp’s mechanisms of action through its binding to erythropoietin receptors on erythroid progenitor cells. The compound serves as an essential tool for examining how glycosylation patterns affect EPO receptor activation and downstream signalling cascades. Scientists investigating hematological disorders can analyse how this recombinant protein influences JAK2-STAT5 signalling pathways that regulate erythroid differentiation. Research teams studying erythropoietin compounds often compare Aranesp’s pharmacokinetic profiles with native EPO to understand structure-activity relationships. The compound enables researchers to investigate dose-response relationships in erythropoiesis stimulation while examining potential off-target effects on endothelial cells and neural tissue. Laboratory studies frequently examine Aranesp’s stability characteristics and receptor binding kinetics to advance understanding of protein therapeutics development. Researchers studying metabolic pathways similar to those investigated with selective modulators can examine Aranesp’s effects on cellular energy metabolism during erythropoiesis.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Compound | Darbepoetin alfa (recombinant) |
| Concentration | 20 mcg per vial |
| Manufacturer | Amgen |
| Molecular Weight | ~37,100 Da |
| Storage Temperature | 2-8°C (refrigerated) |
| Shelf Life | Check product labelling |
This pharmaceutical-grade preparation maintains consistent potency when stored according to manufacturer specifications. Research teams studying protein therapeutics alongside peptide compounds can examine Aranesp’s structural stability and compare its glycosylation patterns with other recombinant proteins.
Research Compliance Statement
Aranesp 20 mcg is supplied exclusively for in-vitro laboratory research purposes and scientific investigation. This product is not intended for human consumption, therapeutic use, or any application outside controlled research environments. Researchers must ensure compliance with institutional protocols and applicable regulations governing recombinant protein research. All studies involving this compound should be conducted by qualified personnel in appropriately equipped laboratory facilities with proper safety measures and waste disposal procedures.
